Pluristem Therapeutics, Inc. (PSTI) Monday said independent researchers from the Queensland Lung Transplant Service at the University of Queensland, Australia demonstrated that, following infusion of Pluristem's PLX cells or Placental eXpanded cells in a human lung model of pulmonary arterial hypertension or PAH, blood flows were maintained and no adverse hemodynamic effects were noted.
Commenting on the development, Zami Aberman, Pluristem's Chairman and CEO said, "We are pleased that independent researchers were able to demonstrate the safety of our PLX-PAD cells in this unique human lung model designed to bridge the gap between data obtained from animals and data needed to commence human studies. We look forward to the initiation of Phase I human studies for this important indication."
On June 20, 2011 United Therapeutics and Pluristem entered into a licensing agreement pursuant to which United Therapeutics will develop, market and sell Pluristem's PLX-PAD cells for PAH.
For comments and feedback: editorial@rttnews.com